GAMMA Investing’s RAPT Therapeutics RAPT Stock Holding History

GAMMA Investing’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3	Closed	-$242	–	3501
2024 Q1	$242	Hold	3	–	–	﹤0.01%	3208
2023 Q4	$569	Buy	+3	New	+$371	﹤0.01%	2935

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

GAMMA Investing's RAPT Position: Q2 2024 in Review

GAMMA Investing sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 3 shares — an estimated $242 sold.

GAMMA Investing first reported a position in RAPT in Q4 2023 and held it in 2 quarters. The position peaked at $569 in Q4 2023. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

GAMMA Investing reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
GAMMA Investing sold 3 RAPT Therapeutics shares in Q2 2024, an estimated $242.
GAMMA Investing first reported a position in RAPT Therapeutics in Q4 2023 and held it in 2 quarters.
GAMMA Investing's RAPT Therapeutics position peaked at $569 in Q4 2023.
103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on GAMMA Investing's 13F filing for Q2 2024, filed 2 Jul 2024.